<DOC>
	<DOCNO>NCT02741076</DOCNO>
	<brief_summary>The purpose study evaluate effect pain intensity ( PI ) structure discontinuation long-term opioid analgesic therapy compare continuation opioid therapy Suboptimal Optimal Responders high-dose , long-term opioid analgesic therapy chronic low back pain ( CLBP ) .</brief_summary>
	<brief_title>Structured Discontinuation v Continued Therapy Suboptimal Optimal Responders High-dose Long-term Opioids Chronic Pain</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Oxymorphone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>1 . Be male nonpregnant , nonlactating female age 18 75 year , inclusive . 2 . Have clinical diagnosis nonradicular CLBP ( pain occur area boundary lowest rib crease buttock ) Class 1 proximal radicular ( knee ) pain Class 2 base Quebec Task Force Classification Spinal Disorders ( subject previous surgery chronic pain syndrome , i.e. , class 9.2 10 , allow pain radiate radiates proximally ) minimum 12 month 1 . For Suboptimal Responder group , pain must present least several hour day Average PI score 69 11point NRS within past 24 hour screen . 2 . For Optimal Responder group , subject must Average PI score 14 11point NRS within past 24 hour screen . 3 . Have take ER/LA opioids immediate release opioids ( least 4 time day ) least 12 month . 4 . Have take one 3 index ER opioid drug aroundtheclock twiceaday frequency least 3 consecutive month total daily dose within range show . Daily Dose Range 1 . Morphine sulfate extendedrelease : 120540mg 2 . Oxycodone extendedrelease : 80360mg 3 . Oxymorphone extendedrelease : 40180mg 5 . Be consider , opinion Investigator , generally good health CLBP screening base upon result medical history , physical examination , 12lead ECG , laboratory profile . 6 . Speak , read , write , understand English ( reduce heterogeneity data ) , understand consent form , able effectively communicate study staff . 7 . Have access Internet ( access patient support program ) . 8 . Voluntarily provide write informed consent . 9 . Be willing able complete study procedure . 1 . Have clinically significant condition would , opinion Investigator , preclude study participation interfere assessment pain symptom CLBP increase risk opioidrelated AEs . 2 . Have primary diagnosis fibromyalgia , complex regional pain syndrome , neurogenic claudication due spinal stenosis , spinal cord compression , acute nerve root compression , severe progressive low extremity weakness numbness , bowel bladder dysfunction result cauda equina compression , diabetic amyotrophy , meningitis , diskitis , back pain secondary infection tumor , pain cause confirm suspected neoplasm . 3 . Have undergone surgical procedure back pain within 6 month prior Screening Visit . 4 . Have nerve plexus block , include epidural steroid injection facet block , within 1 month prior Screening Visit botulinum toxin injection lower back region within 3 month prior screen . 5 . Have history confirm malignancy within past 2 year , exception basal cell squamous cell carcinoma skin successfully treat . 6 . Have uncontrolled blood pressure , i.e. , subject sit systolic blood pressure &gt; 180 mm Hg &lt; 90 mm Hg , sit diastolic blood pressure &gt; 110 mmHg &lt; 40 mm Hg screening . 7 . Have body mass index ( BMI ) &gt; 45 kg/m2 . Anyone BMI &gt; 40 &lt; 45 complete screen tool ( STOPBang Questionnaire ) rule high risk obstructive sleep apnea . 8 . Have clinically significant depression base score ≥20 Patient Health Questionnaire ( PHQ8 ) 9 . Have suicidal ideation associate actual intent method plan past year : `` Yes '' answer item 4 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) . 10 . Have previous history suicidal behavior past 5 year : `` Yes '' answer ( event occur past 5 year ) suicidal behavior item CSSRS . 11 . Have lifetime history serious recurrent suicidal behavior . ( Nonsuicidal selfinjurious behavior trigger risk assessment unless Investigator 's judgment indicate . ) 12 . Have clinically significant abnormality clinical chemistry , hematology urinalysis , include serum glutamicoxaloacetic transaminase/aspartate aminotransferase serum glutamic pyruvic transaminase/alanine aminotransferase ≥3 time upper limit reference range serum creatinine &gt; 2 mg/dL screening . 13 . Have severe enough psychiatric substance abuse disorder compromise subject 's safety scientific integrity study . 14 . Have ongoing litigation associate back pain pending application worker compensation disability issue subject plan file litigation claim within next 12 month ; subject settle past litigation allow subject worker compensation disability claim least 3 month . 15 . Have use monoamine oxidase inhibitor within 14 day prior start study medication . 16 . Are take agonistantagonists ( pentazocine , butorphanol nalbuphine ) , buprenorphine , methadone , barbiturate , one type benzodiazepine within 1 month prior screen . 17 . Have positive UDT illicit drug ( include marijuana ) , nonprescribed control substance ( opioid nonopioid ) , alcohol screen . 18 . Have take investigational drug within 30 day prior Screening Visit currently enrol another investigational drug study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>